Viking Therapeutics Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics or view top-rated stocks.

Wall Street analysts have given Viking Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viking Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Viking Therapeutics.

Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its quarterly earnings data on Wednesday, February, 17th. The biotechnology company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15).
View Viking Therapeutics' earnings history.

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VKTX stock has increased by 32.9% and is now trading at $6.74.
View which stocks have been most impacted by COVID-19.

10 analysts have issued 12-month price objectives for Viking Therapeutics' shares. Their forecasts range from $12.00 to $27.00. On average, they expect Viking Therapeutics' share price to reach $16.44 in the next year. This suggests a possible upside of 144.0% from the stock's current price.
View analysts' price targets for Viking Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Viking Therapeutics include Generation Bio (GBIO), Madrigal Pharmaceuticals (MDGL), NGM Biopharmaceuticals (NGM), ADC Therapeutics (ADCT), Endo International (ENDP), Aurinia Pharmaceuticals (AUPH), Pandion Therapeutics (PAND), Revance Therapeutics (RVNC), Seres Therapeutics (MCRB), Shattuck Labs (STTK), Arcutis Biotherapeutics (ARQT), Zentalis Pharmaceuticals (ZNTL), Applied Molecular Transport (AMTI), ImmunoGen (IMGN) and PMV Pharmaceuticals (PMVP).
View all of VKTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.29%), Park West Asset Management LLC (2.04%), Northern Trust Corp (1.85%), Fiera Capital Corp (1.52%), Baker BROS. Advisors LP (0.50%) and Nuveen Asset Management LLC (0.42%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics.

VKTX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, SG Americas Securities LLC, Aviva PLC, Credit Suisse AG, Squarepoint Ops LLC, Trexquant Investment LP, Baker BROS. Advisors LP, and Northern Trust Corp. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc, and Matthew W Foehr.
View insider buying and selling activity for Viking Therapeutics or view top insider-selling stocks.

VKTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, GSA Capital Partners LLP, Wells Fargo & Company MN, Blair William & Co. IL, Virtu Financial LLC, Park West Asset Management LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Viking Therapeutics or or view top insider-buying stocks.

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VKTX stock can currently be purchased for approximately $6.74.

Viking Therapeutics has a market capitalization of $499.66 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

Viking Therapeutics employs 17 workers across the globe.

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

Viking Therapeutics is headquartered at 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]